In this issue:
CAR-T cell therapy optimal for triple-class exposed RRMM
Dual antigen targeted CAR-T cell therapy shows promise in RRMM
DETERMINATION: Early transplant prolongs PFS but not survival vs novel triplet therapy
Magnified survival benefit from upfront ASCT in high-risk disease
Serum paraprotein response kinetics have prognostic value
Comparable outcomes with VCD vs VRD induction prior to ASCT
IMiD and PIs increase the risk for high-grade cardiovascular events
Salvage therapy with dara-KDT-P(A) CE for heavily pre-treated, high-risk RRMM
Pomalidomide-based regimens efficacious after early lenalidomide treatment failure
Hypersialylation represents a novel therapeutic target in MM
Please login below to download this issue (PDF)